AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28988687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889
Study 28988687 — intervention group
Group type: EXPERIMENTAL
Intervention: Orantinib
Number of subjects: 889
Study 26646462 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy group (n = 62)
Number of subjects: 126
Study 26646462 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 64)
Number of subjects: 126
Study 26646462 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy (meta-analysis)
Number of subjects: 126
Study 25937837 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0 mg oral melatonin nightly for 10 weeks
Number of subjects: 39
Study 25937837 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo nightly for 10 weeks
Number of subjects: 39
Study 23355492 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations with resin-composite and GIC lining
Number of subjects: 53
Study 23355492 — intervention group
Group type: COMPARATOR
Intervention: Restorations with resin-composite without GIC lining
Number of subjects: 53
Study 20124733 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH530348 (20 or 40 mg loading dose followed by 1 mg/d or 2.5 mg/d for 60 days)
Number of subjects: 117
Study 20124733 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (aspirin, ticlopidine, and heparin)
Number of subjects: 117
Study 20124733 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH530348 plus standard-of-care
Number of subjects: 117
Study 20124733 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care alone
Number of subjects: 117
Study 19035150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (blood glucose control at 4.4 to 6.1 mmol/L)
Number of subjects: 46
Study 19035150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 46
Study 19035150 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (blood glucose control at 10.0 to 11.1 mmol/L)
Number of subjects: 46
Study 19035150 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 46
Study 17235728 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE chemotherapy (doxorubicin 40 mg/m², cyclophosphamide 1000 mg/m², etoposide 120 mg/m² on day 1 IV, plus oral etoposide 240 mg/m² daily on days 2-3) with pegfilgrastim 6 mg by subcutaneous injection on day 4 of each cycle
Number of subjects: 30
Study 14635368 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 203
Study 14635368 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 203
Study 10996578 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial program (Weight Watchers)
Number of subjects: 423
Study 10996578 — intervention group
Group type: COMPARATOR
Intervention: Self-help program
Number of subjects: 423
Study 8851907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC) 0.3 g.kg body mass‐1
Number of subjects: 7
Study 8851907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) 0.5 g.kg body mass‐1
Number of subjects: 7
Study 8851907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC, wheat flour, 0.5 g.kg body mass‐1)
Number of subjects: 7
Study 1340797 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electronic foetal heart rate monitoring
Number of subjects: 0
Study 1340797 — intervention group
Group type: COMPARATOR
Intervention: Intermittent monitoring using hand held doppler foetal heart rate detector
Number of subjects: 0
Study 6650625 — intervention group
Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 0
Study 6650625 — intervention group
Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 0
Study 6650625 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 0
Study 31607279 — intervention group
Group type: EXPERIMENTAL
Intervention: HitnRun mobile game intervention
Number of subjects: 144
Study 31607279 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational brochure
Number of subjects: 144
Study 30580266 — intervention group
Group type: EXPERIMENTAL
Intervention: goserelin 3.6 mg/28 days by subcutaneous injection plus oral anastrozole 1 mg/day for 12 weeks
Number of subjects: 12
Study 30580266 — intervention group
Group type: COMPARATOR
Intervention: oral tamoxifen 20 mg/day for 12 weeks
Number of subjects: 12
Study 26752186 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participants in the P‐BRC
Number of subjects: 6344
Study 26752186 — intervention group
Group type: COMPARATOR
Intervention: Inactive participants
Number of subjects: 6344
Study 25175762 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple grape juice (pGJ), 6 ounces twice daily for 4 weeks
Number of subjects: 24
Study 25175762 — intervention group
Group type: COMPARATOR
Intervention: Clear apple juice (cAJ), 6 ounces twice daily for 4 weeks
Number of subjects: 24
Study 22341377 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise program (3 months, starting at 16 to 20 weeks of gestation)
Number of subjects: 80
Study 22341377 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (control group)
Number of subjects: 80
Study 20590748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg od for 12 weeks
Number of subjects: 40
Study 20590748 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 40
Study 17520238 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (PIO)
Number of subjects: 15
Study 17520238 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (FENO)
Number of subjects: 15
Study 17520238 — intervention group
Group type: COMPARATOR
Intervention: Addition of FENO to PIO
Number of subjects: 15
Study 17520238 — intervention group
Group type: COMPARATOR
Intervention: Addition of PIO to FENO
Number of subjects: 15
Study 17520238 — intervention group
Group type: EXPERIMENTAL
Intervention: FENO
Number of subjects: 15
Study 16361631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored decision support system (DSS)
Number of subjects: 32
Study 16361631 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 32
Study 12088161 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day, increased to a maximum of 60 mg/day after week 2)
Number of subjects: 45
Study 12088161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol II (early reinduction treatment) for SRG patients
Number of subjects: 218
Study 10438710 — intervention group
Group type: COMPARATOR
Intervention: No early reinduction treatment for SRG patients
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol S (late intensification) for RG patients
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (DCLSG ALL-7)
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: SRG patients receiving protocol II
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: RG patients
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: EG patients
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CNS prophylaxis (systemic high-dose methotrexate and intrathecal chemotherapy)
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CNS relapse rate
Number of subjects: 218
Study 10438710 — intervention group
Group type: COMPARATOR
Intervention: SRG patients not receiving protocol II
Number of subjects: 218
Study 10438710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 218
Study 7489843 — intervention group
Group type: EXPERIMENTAL
Intervention: B10Asp
Number of subjects: 21
Study 7489843 — intervention group
Group type: COMPARATOR
Intervention: Actrapid
Number of subjects: 21
Study 2111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucan (50 mg/m2, intravenously daily for 7 days)
Number of subjects: 38
Study 2111126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously daily for 7 days)
Number of subjects: 38
Study 2111126 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucan
Number of subjects: 38
Study 2111126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 160846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (80 micrograms applied intranasally 4 times a day)
Number of subjects: 20
Study 160846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 160846 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium
Number of subjects: 20
Study 31161947 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 80
Study 31161947 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 80
Study 28786993 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid administration
Number of subjects: 20
Study 28786993 — intervention group
Group type: COMPARATOR
Intervention: Rasburicase administration
Number of subjects: 20
Study 28786993 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 26536700 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of parecoxib sodium 40 mg after surgery, continued with 40 mg injections after 12, 24, and 36 hours.
Number of subjects: 90
Study 26536700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg tramadol after surgery, replacing parecoxib sodium in group C.
Number of subjects: 90
Study 26536700 — intervention group
Group type: COMPARATOR
Intervention: Blank control group without any analgesia measures.
Number of subjects: 90
Study 22859618 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (450 ml daily for 4 weeks)
Number of subjects: 19
Study 22859618 — intervention group
Group type: COMPARATOR
Intervention: De‐alcoholized red wine (450 ml daily for 4 weeks)
Number of subjects: 19
Study 21592388 — intervention group
Group type: EXPERIMENTAL
Intervention: Early STOPP intervention delivered by a trained coach (dietitian, physiotherapist or a nurse) focusing on healthy food choices, increasing physical activity, reducing sedentary behavior, and regulating sleeping patterns.
Number of subjects: 0
Study 21592388 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 19191781 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel treatment
Number of subjects: 47
Study 19191781 — intervention group
Group type: COMPARATOR
Intervention: Every 3 weeks paclitaxel treatment
Number of subjects: 47
Study 16790607 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of nitrous oxide/oxygen (N2O/O2)
Number of subjects: 90
Study 16790607 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 90
Study 12765500 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, standardised debriefing session based on critical incident stress debriefing principles within 72 hours of delivery
Number of subjects: 1745
Study 12765500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no debriefing)
Number of subjects: 1745
Study 12765500 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual, standardised debriefing session
Number of subjects: 1745
Study 10857142 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg per day in single dose)
Number of subjects: 74
Study 10857142 — intervention group
Group type: COMPARATOR
Intervention: Alfuzosin (7.5 mg per day in 3 doses)
Number of subjects: 74
Study 9358213 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU monotherapy (600 mg/m2)
Number of subjects: 49
Study 9358213 — intervention group
Group type: COMPARATOR
Intervention: Combination of 5-FU (600 or 400 mg/m2) and high-dose FA (400 mg/m2)
Number of subjects: 49
Study 8257226 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (0.5 mg)
Number of subjects: 23
Study 8257226 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 unit)
Number of subjects: 23
Study 8257226 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal
Number of subjects: 23
Study 4037436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control measures alone
Number of subjects: 12
Study 4037436 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust control measures combined with electrostatic and high efficiency particulate air filters
Number of subjects: 12
Study 4037436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31430286 — intervention group
Group type: EXPERIMENTAL
Intervention: Health System Strengthening (HSS) intervention
Number of subjects: 1514
Study 31430286 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 1514
Study 29528768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet rich in multiple functional foods (LE + FF)
Number of subjects: 90
Study 29528768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet (LE)
Number of subjects: 90
Study 29528768 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 90
Study 25403253 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiological taping
Number of subjects: 70
Study 25403253 — intervention group
Group type: COMPARATOR
Intervention: Subacromial injection therapy (Betamethasone plus prilocaine)
Number of subjects: 70
Study 25202858 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic administration of fresh frozen plasma (FFP)
Number of subjects: 55
Study 23131815 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary social support
Number of subjects: 178
Study 23131815 — intervention group
Group type: EXPERIMENTAL
Intervention: Life dissatisfaction
Number of subjects: 178
Study 19384779 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL optic captured behind the posterior capsule with posterior capsulotomy (group 1)
Number of subjects: 73
Study 19384779 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL optic implanted in the bag with posterior capsulotomy (group 2)
Number of subjects: 73
Study 19384779 — intervention group
Group type: EXPERIMENTAL
Intervention: IOL optic implanted in the bag without posterior capsulotomy (group 3)
Number of subjects: 73
Study 17718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual components (Lv)
Number of subjects: 0
Study 17718367 — intervention group
Group type: COMPARATOR
Intervention: Visual components (Sv)
Number of subjects: 0
Study 17718367 — intervention group
Group type: COMPARATOR
Intervention: Auditory components (La)
Number of subjects: 0
Study 17718367 — intervention group
Group type: COMPARATOR
Intervention: Auditory components (Sa)
Number of subjects: 0
Study 15279342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-free formula (Dumex Lactose-Free Formula)
Number of subjects: 80
Study 15279342 — intervention group
Group type: COMPARATOR
Intervention: Lactose-containing formula (Dumex Infant Formula)
Number of subjects: 80
Study 12148300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5% (4 ml) injected retrobulbarly before surgery (group I)
Number of subjects: 45
Study 12148300 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacain 0.5% (4 ml) injected retrobulbarly after surgery (group II)
Number of subjects: 45
Study 12148300 — intervention group
Group type: COMPARATOR
Intervention: No retrobulbar anesthesia (group III)
Number of subjects: 45
Study 9586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy with selective, long‐acting, alpha1‐blocking agents (terazosin, doxazosin, tamsulosin)
Number of subjects: 0
Study 9586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5‐alpha‐reductase inhibitor)
Number of subjects: 0
Study 9586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Device therapies (Laser prostatectomy including VLAP, TUEP, TILP)
Number of subjects: 0
Study 9586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical strategies
Number of subjects: 0
Study 9586589 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and device therapies
Number of subjects: 0
Study 7862899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 ml/kg body weight)
Number of subjects: 0
Study 7862899 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatments
Number of subjects: 0
Study 7862899 — intervention group
Group type: COMPARATOR
Intervention: Alcohol treatments
Number of subjects: 0
Study 2536911 — intervention group
Group type: COMPARATOR
Intervention: MAC chemotherapy (methotrexate, dactinomycin, and chlorambucil)
Number of subjects: 42
Study 2536911 — intervention group
Group type: EXPERIMENTAL
Intervention: modified CHAMOMA regimen (methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine)
Number of subjects: 42
Study 259 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal cannula
Number of subjects: 150
Study 259 — intervention group
Group type: COMPARATOR
Intervention: Plastic cannula
Number of subjects: 150
Study 31977104 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 1003
Study 31977104 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter intervention
Number of subjects: 1003
Study 31977104 — intervention group
Group type: COMPARATOR
Intervention: No-contact control condition
Number of subjects: 1003
Study 30535516 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV after early extubation
Number of subjects: 130
Study 30535516 — intervention group
Group type: COMPARATOR
Intervention: Standard extubation
Number of subjects: 130
Study 28958137 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 45
Study 28958137 — intervention group
Group type: EXPERIMENTAL
Intervention: Temperature controlled High Energy Adjustable multi-mode emission Laser (THEAL)
Number of subjects: 45
Study 28958137 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Number of subjects: 45
Study 25590507 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 37
Study 25590507 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide
Number of subjects: 37
Study 23235439 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery group (ES)
Number of subjects: 54
Study 23235439 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 54
Study 23235439 — intervention group
Group type: COMPARATOR
Intervention: Comparison of CDGAS differences between ES and CO
Number of subjects: 54
Study 23235439 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 54
Study 21553981 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention formation
Number of subjects: 227
Study 21553981 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 227
Study 17947605 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral formula containing 50 g of saccharides enriched with 2.3 g of fiber/100 mL
Number of subjects: 10
Study 17947605 — intervention group
Group type: COMPARATOR
Intervention: Enteral formula containing 50 g of saccharides
Number of subjects: 10
Study 15618070 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 1749
Study 15618070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1749
Study 12131722 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional open MRI
Number of subjects: 29
Study 12131722 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with no history of low back pain
Number of subjects: 29
Study 9621141 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN-beta (0.15 x 10(6) IU/g) applied 5 times daily for 4 weeks
Number of subjects: 120
Study 9621141 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IFN-beta (1.0 x 10(6) IU/g) applied 5 times daily for 4 weeks
Number of subjects: 120
Study 9621141 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied 5 times daily for 4 weeks
Number of subjects: 120
Study 7633951 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream (2 x 10(6) IU/g) applied three times daily for 5 consecutive days
Number of subjects: 60
Study 7633951 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied three times daily for 5 consecutive days
Number of subjects: 60
Study 7633951 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon-alpha cream
Number of subjects: 60
Study 2752873 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 2752873 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 0
Study 330080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac given twice daily (100 to 300 mg daily, adjusted according to patient response)
Number of subjects: 91
Study 330080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac given 4 times daily (100 to 300 mg daily, adjusted according to patient response)
Number of subjects: 91
Study 330080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 31609870 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-delivered foot reflexology for patients (15 days, once a day)
Number of subjects: 60
Study 31609870 — intervention group
Group type: COMPARATOR
Intervention: Control group (reading session)
Number of subjects: 60
Study 31609870 — intervention group
Group type: COMPARATOR
Intervention: Caregiver-delivered foot reflexology and control group (reading session)
Number of subjects: 60
Study 28556581 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (Uptravi)
Number of subjects: 1156
Study 28556581 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (Uptravi) with PAH comedication
Number of subjects: 1156
Study 28556581 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1156
Study 26321524 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng granules, 10 g/time, tid for 2 courses
Number of subjects: 58
Study 26321524 — intervention group
Group type: COMPARATOR
Intervention: Synchronous radiotherapy and chemotherapy (Control)
Number of subjects: 58
Study 26321524 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng granules
Number of subjects: 58